Colesterol Dietético, Ingestão de Carboidratos e Modificação da Lipoproteína de Baixa Densidade: Revisitando o Papel da Gordura Animal na Doença Cardiovascular

Dr. Claudio Amichetti Junior — CRMV 75404. Pós-graduado em Nutrição Animal, Pós-graduado em Farmacologia, Pós-graduado em Cannabis Medicinal.

RESUMO

A hipótese de que o colesterol dietético e a gordura animal são os principais fatores dietéticos da aterosclerose domina a nutrição cardiovascular há mais de seis décadas. Contudo, evidências contemporâneas indicam que a aterogenicidade da lipoproteína de baixa densidade (LDL) depende menos da sua concentração plasmática isolada e mais da sua modificação qualitativa — em particular oxidação e glicação impulsionadas por hiperglicemia crônica e altas cargas glicêmicas. Esta revisão narrativa examina a construção histórica do dogma dieta-coração, incluindo influência documentada da indústria do açúcar sobre as pesquisas da época; o papel mecanístico da ingestão de carboidratos na produção de partículas de LDL pequenas, densas, oxidadas e glicadas; a fraca correlação entre colesterol dietético e sérico; e os papéis fisiológicos essenciais do colesterol como precursor de hormônios esteroides, cortisol, vitamina D e membranas celulares. Apresenta-se uma avaliação equilibrada das evidências, reconhecendo que a redução de carboidratos — especialmente carboidratos refinados e açúcares adicionados, e não a gordura saturada — parece ser a estratégia dietética mais eficaz para a dislipidemia aterogênica, ao mesmo tempo em que se reconhecem pontos legítimos de controvérsia. Discutem-se implicações para a prática clínica e para a comunicação em saúde pública.

PALAVRAS-CHAVE: colesterol dietético; gordura saturada; oxidação da LDL; LDL glicada; dislipidemia aterogênica; ingestão de carboidratos; açúcares adicionados; hipótese dieta-coração; esteroidogênese; sintomas musculares associados a estatinas.

1. INTRODUÇÃO

A doença cardiovascular (DCV) segue como principal causa de morte no mundo, e a orientação dietética para sua prevenção foi dominada por décadas por uma única narrativa: o colesterol dietético e a gordura saturada de origem animal elevam o colesterol sanguíneo e, portanto, causam aterosclerose. Essa narrativa, frequentemente chamada de hipótese dieta-coração, moldou as diretrizes alimentares nacionais a partir dos anos 1960 e levou gerações de profissionais de saúde a orientar pacientes a evitar gemas de ovo, manteiga, banha e cortes gordos de carne. Em paralelo, a ingestão de carboidratos — em particular carboidratos refinados e açúcares adicionados — expandiu-se substancialmente no mesmo período, em parte como consequência das recomendações de redução de gordura.

Um conjunto crescente de evidências mecanísticas e epidemiológicas hoje sustenta uma leitura diferente dos dados: o fenótipo lipoproteico mais aterogênico não é simplesmente "colesterol alto", mas um padrão de partículas de LDL pequenas, densas, oxidadas e glicadas, impulsionado em grande parte por dietas ricas em carboidratos, resistência à insulina e hiperglicemia pós-prandial crônica. Esta revisão retoma as origens do dogma do colesterol, os mecanismos pelos quais a ingestão de carboidratos modifica a LDL, a fraca relação entre colesterol dietético e sérico e os papéis fisiológicos indispensáveis do colesterol — argumentando que a equação simplista "gordura animal = aterosclerose" merece revisão crítica.

2. CONSTRUÇÃO HISTÓRICA DO DOGMA DIETA-CORAÇÃO

Os debates iniciais sobre as causas dietéticas da doença arterial coronariana (DAC) nas décadas de 1950 e 1960 não ocorreram livres de interesses comerciais. Uma análise histórica de documentos internos da Sugar Research Foundation (SRF) mostrou que, em 1965, a SRF patrocinou uma revisão de literatura publicada no New England Journal of Medicine que apontou gordura e colesterol como as causas dietéticas da DAC, minimizando evidências emergentes que implicavam a sacarose — e que o financiamento e o papel da fundação não foram divulgados (Kearns et al., 2016). Os autores concluíram que a indústria do açúcar patrocinou, nos anos 1960 e 1970, um programa de pesquisa que "lançou com sucesso dúvidas sobre os perigos da sacarose, promovendo a gordura como o culpado dietético da DAC".

Esse contexto histórico importa porque o paradigma resultante — gordura e colesterol como vilões, carboidratos como substitutos inocentes — se enraizou nas diretrizes alimentares, na formação profissional e na percepção pública. DiNicolantonio, Lucan e O'Keefe (2015) reexaminaram as evidências sobre gordura saturada versus açúcares adicionados em relação à doença coronariana e concluíram que as evidências que implicam os açúcares adicionados são mais fortes do que as que implicam a gordura saturada, e que a substituição da gordura saturada por carboidratos refinados pode ter agravado o risco cardiovascular em nível populacional. Notavelmente, as décadas em que a epidemiologia cardiovascular se expandiu foram também as décadas de maior expansão no consumo de carboidratos refinados — uma coincidência temporal que, no mínimo, justifica escrutínio das atribuições causais feitas naquela época.

3. LDL: UM TRANSPORTADOR, NÃO O PRÓPRIO CULPADO

Um erro conceitual comum na comunicação clínica é tratar a LDL como "colesterol ruim". Estritamente, a LDL é uma partícula lipoproteica — um carreador — cuja função é transportar colesterol pela corrente sanguínea. O colesterol é uma molécula; a LDL é o veículo. O processo aterogênico depende criticamente do que acontece com a partícula: a LDL nativa captada por receptores de LDL faz parte da fisiologia normal, enquanto a LDL modificada (oxidada, glicada, agregada) é captada por receptores scavenger nos macrófagos, promovendo formação de células espumosas e desenvolvimento de placa.

A hiperglicemia é um motor central dessa modificação. A glicação não enzimática da LDL produz produtos finais de glicação avançada (AGEs), incluindo a Nε-(carboximetil)lisina (CML) na apolipoproteína B. No diabetes tipo 2, a formação excessiva de CML na LDL prejudica sua depuração via receptores de LDL, ao mesmo tempo em que intensifica a captação por receptores scavenger e de AGE em macrófagos e células vasculares, acelerando a aterogênese (Ahmed et al., 2008). Uma revisão narrativa contemporânea sumarizou que a hiperglicemia crônica favorece a glicação não enzimática, aumenta a produção de AGEs, induz estresse oxidativo e inflamação, e converte partículas de LDL pequenas e densas em LDL glicada — partículas ainda mais aterogênicas, que conferem risco cardiovascular aumentado (Vekić et al., 2023). Em outras palavras: a mesma concentração plasmática de LDL pode ser muito mais aterogênica em um ambiente metabólico hiperglicêmico, insulinorresistente e rico em carboidratos do que em um ambiente euglicêmico.

4. INGESTÃO DE CARBOIDRATOS E DISLIPIDEMIA ATEROGÊNICA

A dislipidemia aterogênica — a combinação de lipoproteínas ricas em triglicerídeos elevadas, aumento de partículas de LDL pequenas e densas e colesterol HDL reduzido — é o padrão lipídico característico da resistência à insulina e da síndrome metabólica. As evidências de que o carboidrato dietético, e não a gordura saturada, é o principal motor dietético desse padrão são hoje substanciais:

• Em uma meta-análise de estudos de coorte prospectivos, Siri-Tarino et al. (2010) não encontraram evidência significativa de que maior ingestão de gordura saturada se associe a maior risco de doença cardiovascular ou mortalidade, e destacaram que o macronutriente que substitui a gordura saturada (o carboidrato) modifica criticamente o desfecho.
• Lambadiari et al. (2020) revisaram o impacto do índice e da carga glicêmica na cinética lipídica pós-prandial, descrevendo como os carboidratos — especialmente a frutose, que estimula a lipogênese de novo hepática — exacerbam a hipertrigliceridemia pós-prandial, um fator de risco cardiovascular distinto que gera partículas altamente aterogênicas e inflamação endotelial.
• Em revisão de 2025, Kim, Shin e Krauss concluíram que a redução da ingestão de carboidratos é a abordagem dietética mais eficaz para o manejo da dislipidemia aterogênica, particularmente em indivíduos com adiposidade excessiva ou síndrome metabólica, e que limitar a gordura saturada para reduzir o colesterol LDL não demonstrou impacto sobre a dislipidemia aterogênica; recomendam padrões alimentares que enfatizam a moderação da ingestão de carboidratos — especialmente grãos processados e açúcares adicionados — em vez da restrição primária de gordura saturada.

Esses achados se alinham à observação clínica, popularizada em comunidades low-carbohydrate e carnívora-adjacentes, de que pacientes que restringem carboidratos refinados frequentemente apresentam redução de triglicerídeos, aumento de HDL e deslocamento da distribuição de partículas de LDL para fenótipos maiores e mais flutuantes (menos aterogênicos). É importante, porém, precisar a afirmação: não se afirma que a concentração de colesterol LDL seja irrelevante, mas que a modificação qualitativa da LDL impulsionada por carboidratos (partículas pequenas e densas, oxidadas, glicadas) é um mecanismo aterogênico importante — e historicamente subenfático.

5. COLESTEROL DIETÉTICO VERSUS COLESTEROL SÉRICO: UMA CORRELAÇÃO FRACA

A suposição de que comer colesterol eleva o colesterol sanguíneo de forma clinicamente relevante foi repetidamente contestada. Fernández e Murillo (2022) revisaram dados epidemiológicos e intervenções clínicas e concluíram que há falta de correlação entre colesterol dietético e colesterol sanguíneo, com intervenções de desafio de colesterol relatando inclusive efeitos benéficos sobre subfrações de lipoproteínas, colesterol HDL e funcionalidade do HDL. Isso é consistente com a fisiologia compensatória humana: a síntese hepática de colesterol se regula para baixo em resposta à ingestão dietética na maioria dos indivíduos ("compensadores"), e apenas uma minoria de "hiper-respondedores" apresenta elevações significativas.

A literatura sobre ovos ilustra a controvérsia. Uma grande meta-análise atualizada de estudos de coorte (Zhao et al., 2022) relatou associações modestas entre maior ingestão de ovos e colesterol dietético e mortalidade (risco relativo agrupado de 1,04 por ovo adicional de 50 g/dia para mortalidade cardiovascular), sustentando uma posição cautelosa. Em contraste, uma revisão abrangente de 2026 concluiu que meta-análises recentes mostram impacto limitado ou nulo do consumo de ovos sobre aterosclerose e risco de doença cardiovascular, que estudos clínicos relatam melhora do colesterol HDL e redução da LDL oxidada com o consumo adicional de um ovo diário, e que análises ecológicas mundiais identificam associação negativa significativa entre ingestão de ovos e incidência e mortalidade por cardiopatia isquêmica (Kishimoto e Sugihara, 2026). A síntese honesta é que o colesterol dietético é um fator fraco e dependente de contexto — dominado pelo milieu metabólico (resistência à insulina, hiperglicemia, inflamação) em que é consumido — e que a demonização generalizada de alimentos de origem animal ricos em colesterol, como os ovos, não é sustentada pelo conjunto das evidências.

6. OS PAPÉIS FISIOLÓGICOS DO COLESTEROL E DA GORDURA ANIMAL

O colesterol não é uma toxina; é uma pedra angular estrutural e hormonal da biologia dos vertebrados:

• Membranas celulares: o colesterol modula a fluidez e a integridade da membrana em todas as células nucleadas.
• Esteroidogênese: o colesterol é o precursor obrigatório de todos os hormônios esteroides — progesterona, estrogênios, testosterona e cortisol. A restrição dietética crônica de colesterol e gordura animal pode, plausivelmente, limitar a disponibilidade de substrato para a esteroidogênese, mecanismo consistente com a fadiga, a redução da resiliência ao estresse e as queixas hormonais relatadas por pacientes em dietas muito pobres em gordura. Esse argumento de disponibilidade de substrato é fisiologicamente plausível, mas deve ser enquadrado como hipótese que exige ensaios de intervenção diretos.
• Vitamina D e ácidos biliares: o colesterol é o precursor da vitamina D3 e dos ácidos biliares, essenciais para a digestão de gorduras e para a circulação enterohepática.
• Fisiologia digestiva: a gordura animal estimula a liberação de bile e a secreção de lipase pancreática; a instrução clínica comum de que pacientes sem vesícula (ou com queixas biliares) devem evitar gordura confunde ausência de órgão com incapacidade metabólica, e pode agravar a própria intolerância que visa prevenir, perpetuando o baixo fluxo biliar.

Quanto às estatinas, a classe de hipolipemiantes mais prescrita inibe a HMG-CoA redutase, bloqueando não apenas a síntese hepática de colesterol, mas também o intermediário da via do mevalonato coenzima Q10 (ubiquinona), essencial para a produção mitocondrial de ATP. Os sintomas musculares associados a estatinas são questão clínica reconhecida, e a depleção de CoQ10 foi proposta como mecanismo contribuinte, embora as evidências randomizadas sobre suplementação de CoQ10 permaneçam mistas (Zaleski et al., 2018). Isso não nega o benefício comprovado das estatinas na prevenção secundária, mas justifica uma conversa mais nuançada e centrada no paciente sobre trade-offs metabólicos — e reforça o princípio de que a qualidade dietética deve ser a base, com a farmacoterapia sobreposta ao risco individualizado.

7. AVALIAÇÃO CRÍTICA: O QUE AS EVIDÊNCIAS SUSTENTAM E O QUE NÃO SUSTENTAM

A integridade científica exige apresentar a contraprova. Dados meta-analíticos mostram consistentemente que a substituição de gorduras insaturadas por gorduras saturadas eleva o colesterol LDL (uma revisão guarda-chuva de óleos tropicais constatou que substituir óleos insaturados por banha aumentou o LDL-C em aproximadamente 8–10 mg/dL) (Unhapipatpong et al., 2021), e grandes análises de coorte associam maior colesterol dietético a mortalidade modestamente maior (Zhao et al., 2022). O mainstream científico continua a apoiar a redução do colesterol LDL em pacientes de alto risco.

A posição defensável e baseada em evidências não é, portanto, "o colesterol é inofensivo", mas sim uma reordenação de prioridades:

1. A aterogenicidade da LDL é fortemente modificada pelo ambiente metabólico impulsionado por carboidratos (glicação, oxidação, fenótipo pequeno-denso).

2. O colesterol dietético de alimentos animais integrais tem relação fraca e heterogênea com o colesterol sérico e os desfechos cardiovasculares.

3. Reduzir carboidratos refinados e açúcares adicionados é a alavanca dietética mais eficaz contra a dislipidemia aterogênica (Kim et al., 2025).

4. O colesterol e a gordura animal são substratos fisiologicamente indispensáveis, e sua restrição generalizada tem custos plausíveis (esteroidogênese, saciedade, absorção de vitaminas lipossolúveis) que merecem igual atenção científica.

5. Alegações na mídia popular — em ambas as direções — frequentemente exageram narrativas de mecanismo único; padrões alimentares integrados e o contexto específico do paciente superam intervenções isoladas.

8. CONCLUSÃO

O dogma de que o colesterol dietético e a gordura animal são as principais causas dietéticas da aterosclerose foi consolidado em uma era de influência industrial documentada e foi apenas parcialmente revisado pelas evidências subsequentes. A ciência atual sustenta um modelo mais preciso: a ingestão de carboidratos — em particular carboidratos refinados e açúcares adicionados — alimenta o milieu hiperglicêmico e insulinorresistente que oxida e glica as partículas de LDL, produzindo as espécies lipoproteicas mais aterogênicas; ao mesmo tempo, o colesterol de alimentos de origem animal é um determinante fraco do colesterol sérico e um substrato essencial para hormônios, vitamina D, ácidos biliares e membranas celulares. A nutrição clínica deve migrar de uma obsessão univariável pela concentração de colesterol LDL para uma abordagem de contexto metabólico: moderar a ingestão de carboidratos refinados, preservar quantidade e qualidade adequadas de gordura dietética, individualizar a terapia hipolipemiante e comunicar honestamente com os pacientes sobre as incertezas genuínas que permanecem.

REFERÊNCIAS

1. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr. 2010;91(3):502-509. doi:10.3945/ajcn.2008.26285

2. DiNicolantonio JJ, Lucan SC, O'Keefe JH. The Evidence for Saturated Fat and for Sugar Related to Coronary Heart Disease. Prog Cardiovasc Dis. 2016;58(5):464-472. doi:10.1016/j.pcad.2015.11.006

3. Kearns CE, Schmidt LA, Glantz SA. Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents. JAMA Intern Med. 2016;176(11):1680-1685. doi:10.1001/jamainternmed.2016.5394

4. Ahmed KA, Muniandy S, Ismail IS. Nε-(Carboxymethyl)lysine and coronary atherosclerosis-associated low density lipoprotein abnormalities in type 2 diabetes. J Clin Biochem Nutr. 2008;44(1):14-27. doi:10.3164/jcbn.08-190

5. Vekić J, Vujčić S, Bufan B, et al. The Role of Advanced Glycation End Products on Dyslipidemia. Metabolites. 2023;13(1):77. doi:10.3390/metabo13010077

6. Fernández ML, Murillo AG. Is There a Correlation between Dietary and Blood Cholesterol? Evidence from Epidemiological Data and Clinical Interventions. Nutrients. 2022;14(10):2168. doi:10.3390/nu14102168

7. Zhao B, Gan L, Graubard BI, Männistö S, Albanes D, Huang J. Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality. Circulation. 2022;145(14):1081-1095. doi:10.1161/CIRCULATIONAHA.121.057642

8. Kishimoto Y, Sugihara N. Egg Consumption and Human Health: A Comprehensive Review of the Effects on Serum Lipids, Antioxidant Status, and Cardiovascular Outcomes. J Poult Sci. 2026. doi:10.2141/jpsa.2026001

9. Lambadiari V, Korakas E, Tsimihodimos V. The Impact of Dietary Glycemic Index and Glycemic Load on Postprandial Lipid Kinetics, Dyslipidemia and Cardiovascular Risk. Nutrients. 2020;12(8):2204. doi:10.3390/nu12082204

10. Kim S, Shin MJ, Krauss RM. Dietary Management of Atherogenic Dyslipidemia. Curr Atheroscler Rep. 2025. doi:10.1007/s11883-025-01335-6

11. Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms—A Good Idea, but… Adv Nutr. 2018;9(4):505-513. doi:10.1093/advances/nmy010

12. Unhapipatpong C, et al. Tropical Oil Consumption and Cardiovascular Disease: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients. 2021;13(5):1549. doi:10.3390/nu13051549

—

Claudio Amichetti Junior — CRMV 75404

Pós em Nutrição Animal · Pós em Farmacologia · Pós em Cannabis Medicinal

 

Dietary Cholesterol, Carbohydrate Intake, and Low-Density Lipoprotein Modification: Revisiting the Role of Animal Fat in Cardiovascular Disease

Claudio Amichetti Junior — CRMV 75404. Postgraduate in Animal Nutrition, Postgraduate in Pharmacology, Postgraduate in Medicinal Cannabis.

ABSTRACT

The hypothesis that dietary cholesterol and animal fat are the primary dietary drivers of atherosclerosis has dominated cardiovascular nutrition for over six decades. However, contemporary evidence indicates that the atherogenicity of low-density lipoprotein (LDL) depends less on its plasma concentration alone and more on its qualitative modification — particularly oxidation and glycation driven by chronic hyperglycemia and high glycemic loads. This narrative review examines the historical construction of the diet–heart dogma, including documented sugar-industry influence on early research; the mechanistic role of carbohydrate intake in producing small, dense, oxidized and glycated LDL particles; the weak correlation between dietary and serum cholesterol; and the essential physiological roles of cholesterol as precursor of steroid hormones, cortisol, vitamin D, and cell membranes. A balanced appraisal of the evidence is presented, acknowledging that reducing carbohydrates — especially refined carbohydrates and added sugars — rather than saturated fat appears to be the most effective dietary strategy for atherogenic dyslipidemia, while recognizing legitimate points of controversy. Implications for clinical practice and public health communication are discussed.

KEYWORDS: dietary cholesterol; saturated fat; LDL oxidation; glycated LDL; atherogenic dyslipidemia; carbohydrate intake; added sugars; diet–heart hypothesis; steroidogenesis; statin-associated muscle symptoms.

1. INTRODUCTION

Cardiovascular disease (CVD) remains the leading cause of death worldwide, and dietary guidance for its prevention has been dominated for decades by a single narrative: that dietary cholesterol and saturated fat from animal sources raise blood cholesterol and, therefore, cause atherosclerosis. This narrative, often called the diet–heart hypothesis, shaped national dietary guidelines from the 1960s onward and led generations of health professionals to counsel patients to avoid egg yolks, butter, lard, and fatty cuts of meat. In parallel, carbohydrate intake — particularly refined carbohydrates and added sugars — expanded substantially during the same period, in part as a consequence of fat-reduction recommendations.

A growing body of mechanistic and epidemiological evidence now supports a different reading of the data: the most atherogenic lipoprotein phenotype is not simply "high cholesterol," but a pattern of small, dense, oxidized, and glycated LDL particles driven largely by high-carbohydrate diets, insulin resistance, and chronic postprandial hyperglycemia. This review revisits the origins of the cholesterol dogma, the mechanisms by which carbohydrate intake modifies LDL, the weak relationship between dietary and serum cholesterol, and the indispensable physiological roles of cholesterol — arguing that the simplistic equation "animal fat = atherosclerosis" deserves critical revision.

2. HISTORICAL CONSTRUCTION OF THE DIET–HEART DOGMA

The early debates about the dietary causes of coronary heart disease (CHD) in the 1950s and 1960s were not conducted free of commercial interests. A historical analysis of internal Sugar Research Foundation (SRF) documents showed that, in 1965, the SRF sponsored a literature review published in the New England Journal of Medicine that singled out fat and cholesterol as the dietary causes of CHD while downplaying emerging evidence implicating sucrose — and that the foundation's funding and role were not disclosed (Kearns et al., 2016). The authors concluded that the sugar industry sponsored a research program in the 1960s and 1970s that successfully cast doubt about the hazards of sucrose while promoting fat as the dietary culprit in CHD.

This historical context matters because the resulting paradigm — fat and cholesterol as villains, carbohydrates as innocent replacements — became embedded in dietary guidelines, professional education, and public perception. DiNicolantonio, Lucan and O'Keefe (2015) re-examined the evidence for saturated fat versus added sugars in relation to coronary heart disease and concluded that the evidence implicating added sugars is stronger than the evidence implicating saturated fat, and that substituting saturated fat with refined carbohydrates may have worsened cardiovascular risk at the population level. Notably, the decades in which cardiovascular epidemiology expanded were also the decades of the greatest expansion in refined carbohydrate consumption — a temporal coincidence that, at minimum, warrants scrutiny of the causal attributions made in that era.

3. LDL: A TRANSPORTER, NOT THE CULPRIT ITSELF

A common conceptual error in clinical communication is to treat LDL as "bad cholesterol." Strictly, LDL is a lipoprotein particle — a carrier — whose function is to transport cholesterol through the bloodstream. Cholesterol itself is a single molecule; LDL is the vehicle. The atherogenic process depends critically on what happens to the particle: native LDL taken up by LDL receptors is part of normal physiology, whereas modified LDL (oxidized, glycated, aggregated) is taken up by scavenger receptors on macrophages, promoting foam-cell formation and plaque development.

Hyperglycemia is a central driver of this modification. Non-enzymatic glycation of LDL produces advanced glycation end products (AGEs), including Nε-(carboxymethyl)lysine (CML) on apolipoprotein B. In type 2 diabetes, excessive CML formation on LDL impairs its clearance via LDL receptors while enhancing uptake by scavenger and AGE receptors on macrophages and vascular cells, accelerating atherogenesis (Ahmed et al., 2008). A contemporary narrative review summarized that chronic hyperglycemia favors non-enzymatic glycation, increases AGE production, induces oxidative stress and inflammation, and converts small, dense LDL particles into glycated LDL — particles that are even more atherogenic and confer increased cardiovascular risk (Vekić et al., 2023). In other words: the same plasma LDL concentration can be far more atherogenic in a hyperglycemic, insulin-resistant, high-carbohydrate metabolic environment than in a euglycemic one.

4. CARBOHYDRATE INTAKE AND ATHEROGENIC DYSLIPIDEMIA

Atherogenic dyslipidemia — the combination of elevated triglyceride-rich lipoproteins, increased small, dense LDL particles, and reduced HDL cholesterol — is the characteristic lipid pattern of insulin resistance and metabolic syndrome. The evidence that dietary carbohydrate, rather than saturated fat, is the primary dietary driver of this pattern is now substantial:

• In a meta-analysis of prospective cohort studies, Siri-Tarino et al. (2010) found no significant evidence that higher saturated fat intake is associated with higher cardiovascular disease or mortality risk, and highlighted that the macronutrient replacing saturated fat (carbohydrate) critically modifies the outcome.
• Lambadiari et al. (2020) reviewed the impact of glycemic index and glycemic load on postprandial lipid kinetics, describing how carbohydrates — especially fructose, which stimulates hepatic de novo lipogenesis — exacerbate postprandial hypertriglyceridemia, a distinct cardiovascular risk factor that generates highly atherogenic particles and endothelial inflammation.
• In a 2025 review, Kim, Shin and Krauss concluded that reducing carbohydrate intake is the most effective dietary approach for managing atherogenic dyslipidemia, particularly in individuals with excess adiposity or metabolic syndrome, and that limiting saturated fat for LDL-cholesterol reduction has not been shown to have an impact on atherogenic dyslipidemia; they recommend dietary patterns emphasizing moderation of carbohydrate intake — especially processed grains and added sugars — rather than primary restriction of saturated fat.

These findings align with the clinical observation, popularized in low-carbohydrate and carnivore-adjacent communities, that patients who restrict refined carbohydrates frequently show reductions in triglycerides, increases in HDL, and shifts of LDL particle distribution toward larger, more buoyant (less atherogenic) phenotypes. It is important, however, to state this precisely: the claim is not that LDL-cholesterol concentration is irrelevant, but that carbohydrate-driven qualitative modification of LDL (small dense, oxidized, glycated particles) is a major — and historically underemphasized — atherogenic mechanism.

5. DIETARY CHOLESTEROL VERSUS SERUM CHOLESTEROL: A WEAK CORRELATION

The assumption that eating cholesterol raises blood cholesterol in a clinically meaningful way has been repeatedly challenged. Fernández and Murillo (2022) reviewed epidemiological data and clinical interventions and concluded that there is a lack of correlation between dietary and blood cholesterol, with cholesterol-challenge interventions even reporting beneficial effects on lipoprotein subfractions, HDL cholesterol, and HDL functionality. This is consistent with human compensatory physiology: hepatic cholesterol synthesis downregulates in response to dietary intake in most individuals ("compensators"), and only a minority of "hyper-responders" show meaningful rises.

The egg literature illustrates the controversy. A large updated meta-analysis of cohort studies (Zhao et al., 2022) reported modest associations between higher egg and dietary cholesterol intake and mortality (pooled relative risk of 1.04 per additional 50 g egg/day for cardiovascular mortality), supporting a cautious position. In contrast, a comprehensive 2026 review concluded that recent meta-analyses show limited or no impact of egg consumption on atherosclerosis and cardiovascular disease risk, that clinical studies report improved HDL-cholesterol and decreased oxidized LDL with additional daily egg intake, and that worldwide ecological analyses identify a significant negative association between egg intake and ischemic heart disease incidence and mortality (Kishimoto and Sugihara, 2026). The honest synthesis is that dietary cholesterol is a weak, context-dependent factor — dominated by the metabolic milieu (insulin resistance, hyperglycemia, inflammation) in which it is consumed — and that blanket demonization of cholesterol-rich animal foods such as eggs is not supported by the totality of evidence.

6. THE PHYSIOLOGICAL ROLES OF CHOLESTEROL AND ANIMAL FAT

Cholesterol is not a toxin; it is a structural and hormonal cornerstone of vertebrate biology:

• Cell membranes: cholesterol modulates membrane fluidity and integrity in every nucleated cell.
• Steroidogenesis: cholesterol is the obligate precursor of all steroid hormones — progesterone, estrogens, testosterone, and cortisol. Chronic dietary restriction of cholesterol and animal fat can plausibly limit substrate availability for steroidogenesis, a mechanism consistent with the fatigue, reduced stress resilience, and hormonal complaints reported by patients on very-low-fat diets. This substrate-availability argument is physiologically plausible but should be framed as a hypothesis requiring direct intervention trials.
• Vitamin D and bile acids: cholesterol is the precursor of vitamin D3 and of bile acids, which are essential for fat digestion and for the enterohepatic circulation.
• Digestive physiology: animal fat stimulates bile release and pancreatic lipase secretion; the common clinical instruction that patients without a gallbladder (or with biliary complaints) must avoid fat conflates organ absence with metabolic incapacity, and may worsen the very intolerance it aims to prevent by perpetuating low bile flow.

Regarding statin therapy, the most prescribed class of lipid-lowering drugs inhibits HMG-CoA reductase, thereby blocking not only hepatic cholesterol synthesis but also the mevalonate pathway intermediate coenzyme Q10 (ubiquinone), essential for mitochondrial ATP production. Statin-associated muscle symptoms are a recognized clinical issue, and CoQ10 depletion has been proposed as a contributing mechanism, although randomized evidence on CoQ10 supplementation remains mixed (Zaleski et al., 2018). This does not negate the proven benefit of statins in secondary prevention, but it does justify a more nuanced, patient-centered conversation about metabolic trade-offs — and reinforces the principle that dietary quality should be the foundation, with pharmacotherapy layered on individualized risk.

7. CRITICAL APPRAISAL: WHAT THE EVIDENCE DOES AND DOES NOT SUPPORT

Scientific integrity requires stating the counter-evidence. Meta-analytic data consistently show that replacing unsaturated fats with saturated fats raises LDL-cholesterol (an umbrella review of tropical oils found that substituting lard for unsaturated oils increased LDL-C by approximately 8–10 mg/dL) (Unhapipatpong et al., 2021), and large cohort analyses associate higher dietary cholesterol with modestly higher mortality (Zhao et al., 2022). The scientific mainstream continues to support LDL-cholesterol lowering in high-risk patients.

The defensible, evidence-based position is therefore not "cholesterol is harmless" but rather a reframing of priorities:

1. The atherogenicity of LDL is strongly modified by the carbohydrate-driven metabolic environment (glycation, oxidation, small-dense phenotype).
2. Dietary cholesterol from whole animal foods has a weak and heterogeneous relationship with serum cholesterol and cardiovascular outcomes.
3. Reducing refined carbohydrates and added sugars is the most effective dietary lever against atherogenic dyslipidemia (Kim et al., 2025).
4. Cholesterol and animal fat are physiologically indispensable substrates, and their blanket restriction has plausible costs (steroidogenesis, satiety, fat-soluble vitamin absorption) that deserve equal scientific attention.
5. Claims in popular media — in both directions — frequently overstate single-mechanism narratives; integrated dietary patterns and patient-specific context outperform isolated interventions.

8. CONCLUSION

The dogma that dietary cholesterol and animal fat are the principal dietary causes of atherosclerosis was consolidated in an era of documented industry influence and has been only partially revised by subsequent evidence. Current science supports a more precise model: carbohydrate intake — particularly refined carbohydrates and added sugars — drives the hyperglycemic, insulin-resistant milieu that oxidizes and glycates LDL particles, producing the most atherogenic lipoprotein species; meanwhile, cholesterol from animal foods is a weak determinant of serum cholesterol and an essential substrate for hormones, vitamin D, bile acids, and cell membranes. Clinical nutrition should shift from a single-variable obsession with LDL-cholesterol concentration toward a metabolic-context approach: moderating refined carbohydrate intake, preserving adequate dietary fat quality and quantity, individualizing lipid-lowering therapy, and communicating honestly with patients about the genuine uncertainties that remain.

REFERENCES:

1. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr. 2010;91(3):502-509. doi:10.3945/ajcn.2008.26285
2. DiNicolantonio JJ, Lucan SC, O'Keefe JH. The Evidence for Saturated Fat and for Sugar Related to Coronary Heart Disease. Prog Cardiovasc Dis. 2016;58(5):464-472. doi:10.1016/j.pcad.2015.11.006
3. Kearns CE, Schmidt LA, Glantz SA. Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents. JAMA Intern Med. 2016;176(11):1680-1685. doi:10.1001/jamainternmed.2016.5394
4. Ahmed KA, Muniandy S, Ismail IS. Nε-(Carboxymethyl)lysine and coronary atherosclerosis-associated low density lipoprotein abnormalities in type 2 diabetes. J Clin Biochem Nutr. 2008;44(1):14-27. doi:10.3164/jcbn.08-190
5. Vekić J, Vujčić S, Bufan B, et al. The Role of Advanced Glycation End Products on Dyslipidemia. Metabolites. 2023;13(1):77. doi:10.3390/metabo13010077
6. Fernández ML, Murillo AG. Is There a Correlation between Dietary and Blood Cholesterol? Evidence from Epidemiological Data and Clinical Interventions. Nutrients. 2022;14(10):2168. doi:10.3390/nu14102168
7. Zhao B, Gan L, Graubard BI, Männistö S, Albanes D, Huang J. Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality. Circulation. 2022;145(14):1081-1095. doi:10.1161/CIRCULATIONAHA.121.057642
8. Kishimoto Y, Sugihara N. Egg Consumption and Human Health: A Comprehensive Review of the Effects on Serum Lipids, Antioxidant Status, and Cardiovascular Outcomes. J Poult Sci. 2026. doi:10.2141/jpsa.2026001
9. Lambadiari V, Korakas E, Tsimihodimos V. The Impact of Dietary Glycemic Index and Glycemic Load on Postprandial Lipid Kinetics, Dyslipidemia and Cardiovascular Risk. Nutrients. 2020;12(8):2204. doi:10.3390/nu12082204
10. Kim S, Shin MJ, Krauss RM. Dietary Management of Atherogenic Dyslipidemia. Curr Atheroscler Rep. 2025. doi:10.1007/s11883-025-01335-6
11. Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms—A Good Idea, but… Adv Nutr. 2018;9(4):505-513. doi:10.1093/advances/nmy010
12. Unhapipatpong C, et al. Tropical Oil Consumption and Cardiovascular Disease: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients. 2021;13(5):1549. doi:10.3390/nu13051549

Claudio Amichetti Junior — CRMV 75404

Pós em Nutrição Animal · Pós em Farmacologia · Pós em Cannabis Medicinal

Dietary Cholesterol, Carbohydrate Intake, and Low-Density Lipoprotein Modification: Revisiting the Role of Animal Fat in Cardiovascular Disease

Claudio Amichetti Junior — CRMV 75404. Postgraduate in Animal Nutrition, Postgraduate in Pharmacology, Postgraduate in Medicinal Cannabis.

ABSTRACT

The hypothesis that dietary cholesterol and animal fat are the primary dietary drivers of atherosclerosis has dominated cardiovascular nutrition for over six decades. However, contemporary evidence indicates that the atherogenicity of low-density lipoprotein (LDL) depends less on its plasma concentration alone and more on its qualitative modification — particularly oxidation and glycation driven by chronic hyperglycemia and high glycemic loads. This narrative review examines the historical construction of the diet–heart dogma, including documented sugar-industry influence on early research; the mechanistic role of carbohydrate intake in producing small, dense, oxidized and glycated LDL particles; the weak correlation between dietary and serum cholesterol; and the essential physiological roles of cholesterol as precursor of steroid hormones, cortisol, vitamin D, and cell membranes. A balanced appraisal of the evidence is presented, acknowledging that reducing carbohydrates — especially refined carbohydrates and added sugars — rather than saturated fat appears to be the most effective dietary strategy for atherogenic dyslipidemia, while recognizing legitimate points of controversy. Implications for clinical practice and public health communication are discussed.

KEYWORDS: dietary cholesterol; saturated fat; LDL oxidation; glycated LDL; atherogenic dyslipidemia; carbohydrate intake; added sugars; diet–heart hypothesis; steroidogenesis; statin-associated muscle symptoms.

1. INTRODUCTION

Cardiovascular disease (CVD) remains the leading cause of death worldwide, and dietary guidance for its prevention has been dominated for decades by a single narrative: that dietary cholesterol and saturated fat from animal sources raise blood cholesterol and, therefore, cause atherosclerosis. This narrative, often called the diet–heart hypothesis, shaped national dietary guidelines from the 1960s onward and led generations of health professionals to counsel patients to avoid egg yolks, butter, lard, and fatty cuts of meat. In parallel, carbohydrate intake — particularly refined carbohydrates and added sugars — expanded substantially during the same period, in part as a consequence of fat-reduction recommendations.

A growing body of mechanistic and epidemiological evidence now supports a different reading of the data: the most atherogenic lipoprotein phenotype is not simply "high cholesterol," but a pattern of small, dense, oxidized, and glycated LDL particles driven largely by high-carbohydrate diets, insulin resistance, and chronic postprandial hyperglycemia. This review revisits the origins of the cholesterol dogma, the mechanisms by which carbohydrate intake modifies LDL, the weak relationship between dietary and serum cholesterol, and the indispensable physiological roles of cholesterol — arguing that the simplistic equation "animal fat = atherosclerosis" deserves critical revision.

2. HISTORICAL CONSTRUCTION OF THE DIET–HEART DOGMA

The early debates about the dietary causes of coronary heart disease (CHD) in the 1950s and 1960s were not conducted free of commercial interests. A historical analysis of internal Sugar Research Foundation (SRF) documents showed that, in 1965, the SRF sponsored a literature review published in the New England Journal of Medicine that singled out fat and cholesterol as the dietary causes of CHD while downplaying emerging evidence implicating sucrose — and that the foundation's funding and role were not disclosed (Kearns et al., 2016). The authors concluded that the sugar industry sponsored a research program in the 1960s and 1970s that successfully cast doubt about the hazards of sucrose while promoting fat as the dietary culprit in CHD.

This historical context matters because the resulting paradigm — fat and cholesterol as villains, carbohydrates as innocent replacements — became embedded in dietary guidelines, professional education, and public perception. DiNicolantonio, Lucan and O'Keefe (2015) re-examined the evidence for saturated fat versus added sugars in relation to coronary heart disease and concluded that the evidence implicating added sugars is stronger than the evidence implicating saturated fat, and that substituting saturated fat with refined carbohydrates may have worsened cardiovascular risk at the population level. Notably, the decades in which cardiovascular epidemiology expanded were also the decades of the greatest expansion in refined carbohydrate consumption — a temporal coincidence that, at minimum, warrants scrutiny of the causal attributions made in that era.

3. LDL: A TRANSPORTER, NOT THE CULPRIT ITSELF

A common conceptual error in clinical communication is to treat LDL as "bad cholesterol." Strictly, LDL is a lipoprotein particle — a carrier — whose function is to transport cholesterol through the bloodstream. Cholesterol itself is a single molecule; LDL is the vehicle. The atherogenic process depends critically on what happens to the particle: native LDL taken up by LDL receptors is part of normal physiology, whereas modified LDL (oxidized, glycated, aggregated) is taken up by scavenger receptors on macrophages, promoting foam-cell formation and plaque development.

Hyperglycemia is a central driver of this modification. Non-enzymatic glycation of LDL produces advanced glycation end products (AGEs), including Nε-(carboxymethyl)lysine (CML) on apolipoprotein B. In type 2 diabetes, excessive CML formation on LDL impairs its clearance via LDL receptors while enhancing uptake by scavenger and AGE receptors on macrophages and vascular cells, accelerating atherogenesis (Ahmed et al., 2008). A contemporary narrative review summarized that chronic hyperglycemia favors non-enzymatic glycation, increases AGE production, induces oxidative stress and inflammation, and converts small, dense LDL particles into glycated LDL — particles that are even more atherogenic and confer increased cardiovascular risk (Vekić et al., 2023). In other words: the same plasma LDL concentration can be far more atherogenic in a hyperglycemic, insulin-resistant, high-carbohydrate metabolic environment than in a euglycemic one.

4. CARBOHYDRATE INTAKE AND ATHEROGENIC DYSLIPIDEMIA

Atherogenic dyslipidemia — the combination of elevated triglyceride-rich lipoproteins, increased small, dense LDL particles, and reduced HDL cholesterol — is the characteristic lipid pattern of insulin resistance and metabolic syndrome. The evidence that dietary carbohydrate, rather than saturated fat, is the primary dietary driver of this pattern is now substantial:

• In a meta-analysis of prospective cohort studies, Siri-Tarino et al. (2010) found no significant evidence that higher saturated fat intake is associated with higher cardiovascular disease or mortality risk, and highlighted that the macronutrient replacing saturated fat (carbohydrate) critically modifies the outcome.
• Lambadiari et al. (2020) reviewed the impact of glycemic index and glycemic load on postprandial lipid kinetics, describing how carbohydrates — especially fructose, which stimulates hepatic de novo lipogenesis — exacerbate postprandial hypertriglyceridemia, a distinct cardiovascular risk factor that generates highly atherogenic particles and endothelial inflammation.
• In a 2025 review, Kim, Shin and Krauss concluded that reducing carbohydrate intake is the most effective dietary approach for managing atherogenic dyslipidemia, particularly in individuals with excess adiposity or metabolic syndrome, and that limiting saturated fat for LDL-cholesterol reduction has not been shown to have an impact on atherogenic dyslipidemia; they recommend dietary patterns emphasizing moderation of carbohydrate intake — especially processed grains and added sugars — rather than primary restriction of saturated fat.

These findings align with the clinical observation, popularized in low-carbohydrate and carnivore-adjacent communities, that patients who restrict refined carbohydrates frequently show reductions in triglycerides, increases in HDL, and shifts of LDL particle distribution toward larger, more buoyant (less atherogenic) phenotypes. It is important, however, to state this precisely: the claim is not that LDL-cholesterol concentration is irrelevant, but that carbohydrate-driven qualitative modification of LDL (small dense, oxidized, glycated particles) is a major — and historically underemphasized — atherogenic mechanism.

5. DIETARY CHOLESTEROL VERSUS SERUM CHOLESTEROL: A WEAK CORRELATION

The assumption that eating cholesterol raises blood cholesterol in a clinically meaningful way has been repeatedly challenged. Fernández and Murillo (2022) reviewed epidemiological data and clinical interventions and concluded that there is a lack of correlation between dietary and blood cholesterol, with cholesterol-challenge interventions even reporting beneficial effects on lipoprotein subfractions, HDL cholesterol, and HDL functionality. This is consistent with human compensatory physiology: hepatic cholesterol synthesis downregulates in response to dietary intake in most individuals ("compensators"), and only a minority of "hyper-responders" show meaningful rises.

The egg literature illustrates the controversy. A large updated meta-analysis of cohort studies (Zhao et al., 2022) reported modest associations between higher egg and dietary cholesterol intake and mortality (pooled relative risk of 1.04 per additional 50 g egg/day for cardiovascular mortality), supporting a cautious position. In contrast, a comprehensive 2026 review concluded that recent meta-analyses show limited or no impact of egg consumption on atherosclerosis and cardiovascular disease risk, that clinical studies report improved HDL-cholesterol and decreased oxidized LDL with additional daily egg intake, and that worldwide ecological analyses identify a significant negative association between egg intake and ischemic heart disease incidence and mortality (Kishimoto and Sugihara, 2026). The honest synthesis is that dietary cholesterol is a weak, context-dependent factor — dominated by the metabolic milieu (insulin resistance, hyperglycemia, inflammation) in which it is consumed — and that blanket demonization of cholesterol-rich animal foods such as eggs is not supported by the totality of evidence.

6. THE PHYSIOLOGICAL ROLES OF CHOLESTEROL AND ANIMAL FAT

Cholesterol is not a toxin; it is a structural and hormonal cornerstone of vertebrate biology:

• Cell membranes: cholesterol modulates membrane fluidity and integrity in every nucleated cell.
• Steroidogenesis: cholesterol is the obligate precursor of all steroid hormones — progesterone, estrogens, testosterone, and cortisol. Chronic dietary restriction of cholesterol and animal fat can plausibly limit substrate availability for steroidogenesis, a mechanism consistent with the fatigue, reduced stress resilience, and hormonal complaints reported by patients on very-low-fat diets. This substrate-availability argument is physiologically plausible but should be framed as a hypothesis requiring direct intervention trials.
• Vitamin D and bile acids: cholesterol is the precursor of vitamin D3 and of bile acids, which are essential for fat digestion and for the enterohepatic circulation.
• Digestive physiology: animal fat stimulates bile release and pancreatic lipase secretion; the common clinical instruction that patients without a gallbladder (or with biliary complaints) must avoid fat conflates organ absence with metabolic incapacity, and may worsen the very intolerance it aims to prevent by perpetuating low bile flow.

Regarding statin therapy, the most prescribed class of lipid-lowering drugs inhibits HMG-CoA reductase, thereby blocking not only hepatic cholesterol synthesis but also the mevalonate pathway intermediate coenzyme Q10 (ubiquinone), essential for mitochondrial ATP production. Statin-associated muscle symptoms are a recognized clinical issue, and CoQ10 depletion has been proposed as a contributing mechanism, although randomized evidence on CoQ10 supplementation remains mixed (Zaleski et al., 2018). This does not negate the proven benefit of statins in secondary prevention, but it does justify a more nuanced, patient-centered conversation about metabolic trade-offs — and reinforces the principle that dietary quality should be the foundation, with pharmacotherapy layered on individualized risk.

7. CRITICAL APPRAISAL: WHAT THE EVIDENCE DOES AND DOES NOT SUPPORT

Scientific integrity requires stating the counter-evidence. Meta-analytic data consistently show that replacing unsaturated fats with saturated fats raises LDL-cholesterol (an umbrella review of tropical oils found that substituting lard for unsaturated oils increased LDL-C by approximately 8–10 mg/dL) (Unhapipatpong et al., 2021), and large cohort analyses associate higher dietary cholesterol with modestly higher mortality (Zhao et al., 2022). The scientific mainstream continues to support LDL-cholesterol lowering in high-risk patients.

The defensible, evidence-based position is therefore not "cholesterol is harmless" but rather a reframing of priorities:

1. The atherogenicity of LDL is strongly modified by the carbohydrate-driven metabolic environment (glycation, oxidation, small-dense phenotype).
2. Dietary cholesterol from whole animal foods has a weak and heterogeneous relationship with serum cholesterol and cardiovascular outcomes.
3. Reducing refined carbohydrates and added sugars is the most effective dietary lever against atherogenic dyslipidemia (Kim et al., 2025).
4. Cholesterol and animal fat are physiologically indispensable substrates, and their blanket restriction has plausible costs (steroidogenesis, satiety, fat-soluble vitamin absorption) that deserve equal scientific attention.
5. Claims in popular media — in both directions — frequently overstate single-mechanism narratives; integrated dietary patterns and patient-specific context outperform isolated interventions.

8. CONCLUSION

The dogma that dietary cholesterol and animal fat are the principal dietary causes of atherosclerosis was consolidated in an era of documented industry influence and has been only partially revised by subsequent evidence. Current science supports a more precise model: carbohydrate intake — particularly refined carbohydrates and added sugars — drives the hyperglycemic, insulin-resistant milieu that oxidizes and glycates LDL particles, producing the most atherogenic lipoprotein species; meanwhile, cholesterol from animal foods is a weak determinant of serum cholesterol and an essential substrate for hormones, vitamin D, bile acids, and cell membranes. Clinical nutrition should shift from a single-variable obsession with LDL-cholesterol concentration toward a metabolic-context approach: moderating refined carbohydrate intake, preserving adequate dietary fat quality and quantity, individualizing lipid-lowering therapy, and communicating honestly with patients about the genuine uncertainties that remain.

REFERENCES:

1. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr. 2010;91(3):502-509. doi:10.3945/ajcn.2008.26285
2. DiNicolantonio JJ, Lucan SC, O'Keefe JH. The Evidence for Saturated Fat and for Sugar Related to Coronary Heart Disease. Prog Cardiovasc Dis. 2016;58(5):464-472. doi:10.1016/j.pcad.2015.11.006
3. Kearns CE, Schmidt LA, Glantz SA. Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents. JAMA Intern Med. 2016;176(11):1680-1685. doi:10.1001/jamainternmed.2016.5394
4. Ahmed KA, Muniandy S, Ismail IS. Nε-(Carboxymethyl)lysine and coronary atherosclerosis-associated low density lipoprotein abnormalities in type 2 diabetes. J Clin Biochem Nutr. 2008;44(1):14-27. doi:10.3164/jcbn.08-190
5. Vekić J, Vujčić S, Bufan B, et al. The Role of Advanced Glycation End Products on Dyslipidemia. Metabolites. 2023;13(1):77. doi:10.3390/metabo13010077
6. Fernández ML, Murillo AG. Is There a Correlation between Dietary and Blood Cholesterol? Evidence from Epidemiological Data and Clinical Interventions. Nutrients. 2022;14(10):2168. doi:10.3390/nu14102168
7. Zhao B, Gan L, Graubard BI, Männistö S, Albanes D, Huang J. Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality. Circulation. 2022;145(14):1081-1095. doi:10.1161/CIRCULATIONAHA.121.057642
8. Kishimoto Y, Sugihara N. Egg Consumption and Human Health: A Comprehensive Review of the Effects on Serum Lipids, Antioxidant Status, and Cardiovascular Outcomes. J Poult Sci. 2026. doi:10.2141/jpsa.2026001
9. Lambadiari V, Korakas E, Tsimihodimos V. The Impact of Dietary Glycemic Index and Glycemic Load on Postprandial Lipid Kinetics, Dyslipidemia and Cardiovascular Risk. Nutrients. 2020;12(8):2204. doi:10.3390/nu12082204
10. Kim S, Shin MJ, Krauss RM. Dietary Management of Atherogenic Dyslipidemia. Curr Atheroscler Rep. 2025. doi:10.1007/s11883-025-01335-6
11. Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms—A Good Idea, but… Adv Nutr. 2018;9(4):505-513. doi:10.1093/advances/nmy010
12. Unhapipatpong C, et al. Tropical Oil Consumption and Cardiovascular Disease: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients. 2021;13(5):1549. doi:10.3390/nu13051549

Claudio Amichetti Junior — CRMV 75404

Pós em Nutrição Animal · Pós em Farmacologia · Pós em Cannabis Medicinal

 

 

 

 

 

 

Ver esse post no Instagram

 

 

 

 

 

 

 

 

 

 

 

Um post compartilhado por Amichetti Claudio (@dr.claudio.amichetti)